FDA Approves MedImmune's State-of-the-Art Influenza Vaccine Manufacturing Facility

Bulk Production Capacity Expanded to Up to 90 Million Doses of FluMist(R) Seasonally

29-Dec-2005

MedImmune, Inc. announced that its newly constructed influenza vaccine manufacturing facility in Speke, England has been approved by the U.S. Food and Drug Administration (FDA). The facility allows MedImmune to produce up to 15 million bulk doses per month, or approximately 90 million bulk doses per influenza manufacturing season, of its trivalent, intranasal influenza vaccine, FluMist (Influenza Virus Vaccine Live, Attenuated).

The square footage of the new facility is 10 times larger than MedImmune's existing bulk manufacturing facility in Speke, and features larger testing and storage facilities, as well as automated inoculation capabilities. The facility uses a new filtration process, which is expected to provide greater sterility assurance during bulk production. MedImmune plans to begin manufacturing FluMist at this site in 2006.

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances